Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
44.02
-0.43 (-0.97%)
Jul 21, 2026, 2:01 PM EDT - Market open
Harrow Employees
Harrow had 373 employees as of December 31, 2025. The number of employees decreased by 9 or -2.36% compared to the previous year.
Employees
373
Change (1Y)
-9
Growth (1Y)
-2.36%
Revenue / Employee
$720,308
Profits / Employee
-$40,110
Market Cap
1.64B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 373 | -9 | -2.36% | 373 | 0 |
| Dec 31, 2024 | 382 | 67 | 21.27% | 382 | 0 |
| Dec 31, 2023 | 315 | 98 | 45.16% | 315 | 0 |
| Dec 31, 2022 | 217 | 35 | 19.23% | 217 | 0 |
| Dec 31, 2021 | 182 | 57 | 45.60% | 182 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Trulieve Cannabis | 5,000 |
| Phibro Animal Health | 2,475 |
| HUTCHMED (China) | 1,796 |
| Alvotech | 1,279 |
| ANI Pharmaceuticals | 970 |
| Xeris Biopharma Holdings | 435 |
HROW News
- 1 day ago - Harrow and Samsung Bioepis present interim BYOOVIZ post-marketing data - TheFly
- 1 day ago - Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026 - GlobeNewsWire
- 1 day ago - Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting - GlobeNewsWire
- 20 days ago - Harrow announces commercial launch of Byooviz in the U.S. - TheFly
- 20 days ago - Harrow announces commercial launch of BYOOVIZ in U.S. - TheFly
- 20 days ago - Harrow Announces Commercial Launch of BYOOVIZ® in the United States - GlobeNewsWire
- 20 days ago - Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow - Business Wire
- 5 weeks ago - Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare - GlobeNewsWire